SGLT2 is "highly expressed in early lung adenocarcinoma and its precursor lesions, including atypical adenomatous hyperplasia ...

Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

MADRID — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not actually benefit from them, ...

Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In adults with ...

Uptake of sodium-glucose cotransporter 2 (SGLT2) inhibitors among US patients eligible for treatment according to clinical guidelines is extremely low, no matter their diabetes status, according to ...

Sodium glucose co-transporter-2 (SGLT2) inhibitors do not lead to lower 28-day all-cause mortality compared with usual care or placebo in patients hospitalized with COVID-19, according to ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Starting SGLT2 inhibitors led to a lower risk of eGFR ...

Amsterdam, Netherlands – 28 Aug 2023: Sodium glucose co-transporter-2 (SGLT2) inhibitors do not lead to lower 28-day all-cause mortality compared with usual care or placebo in patients hospitalised ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SGLT2 inhibitors reduce the risks for adverse kidney and ...